In 2019, the prevalence of VHL-CNS-Hb was estimated to be 1.12 cases per 100,000, representing approximately 3,678 patients with VHL-CNS-Hb in the US (Supplemental Figure S1). This evidence concerns the gene GSTM1 and von Hippel-Lindau disease.